LBT Innovations ships first instrument to Germany

Latest News

LBT Innovations (ASX:LBT), a company focused on medical technology automation using artificial intelligence, has announced its joint venture company Clever Culture Systems AG (CCS) has shipped an APAS Independence instrument to a leading laboratory in Germany. 

The company said this non-sale shipment is the first APAS instrument shipped to an operational setting in the northern hemisphere. 

German facility Labor Dr Wisplinghoff in Cologne has commissioned its first APAS Independence instrument following an extensive review in LBT's facilities in Adelaide and at St Vincent’s Hospital in Melbourne. 

Labor Dr Wisplinghoff is the largest clinical laboratory in Germany and one of the largest laboratories in Europe. Based in a newly completed purpose-built laboratory facility in Cologne, Labor Dr Wisplinghoff services hospitals and medical practices. The laboratory, founded in 1977, hosts over 40 medical specialists covering all relevant areas of clinical pathology including clinical microbiology and virology, clinical chemistry, toxicology, endocrinology, haematology, oncology, genetics, anatomical and molecular pathology and cytology.

LBT said its partner CCS is working with Labor Dr Wisplinghoff to create a European APAS centre of excellence to test automation efficiency and clinical validation, in a similar way to the evaluation completed at St Vincent’s Hospital in Melbourne late last year. 

“The placement of the instrument in Labor Dr Wisplinghoff, a globally recognised centre of excellence, gives the APAS Independence a huge boost in credibility in Europe and progresses our commercialisation strategy," said Brent Barnes, CEO and managing director of LBT Innovations.

"Our JV company CCS is focused on ensuring a successful evaluation to leverage this experience into other laboratories in Germany and select EU markets. It will also help us to roll out sales of our APAS Independence instruments in the near future.”